NewAmsterdam Pharma(NASDAQ) NAMSW

Market CapN/A

Since IPO (2021)+156%

5 Year+1,781%

1 Year+56%

1 Month-11%

$19.40

+6.59%

+1.20Today

NewAmsterdam Pharma last closing stock price
Metric	Price	Date
Last close	USD 19.00	2026-07-27

NewAmsterdam Pharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+4.4%	USD 18.20	2026-07-20
1 month	-11.09%	USD 21.37	2026-06-26
3 month	+14.67%	USD 16.57	2026-04-28
Year to date	-17.39%	USD 23.00	2025-12-31
1 year	+55.74%	USD 12.20	2025-07-25
3 year	+840.59%	USD 2.02	2023-07-28
5 year	+1,781.19%	USD 1.01	2021-07-28
Since inception	+156.22%	USD 7.42	2021-02-08

NewAmsterdam Pharma Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$22.57M

Net Income (TTM)

-$212.73M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$19.40

Volume

Open

$19.40

Price

$19.40

Volume

Open

$19.40

Previous Close

$19.40

Daily Range

$19.40 - $19.40

52-Week Range

$10.23 - $30.45

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$19.40

Volume

Open

$19.40

Previous Close

$19.40

Daily Range

$19.40 - $19.40

52-Week Range

$10.23 - $30.45

Estimated Earnings Date

Aug 12, 2026

NAMSW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm focused on developing innovative therapies for metabolic diseases. The company is advancing its lead candidate, obicetrapib, which targets Cholesteryl Ester Transfer Protein (CETP) to improve cholesterol levels.

Products and Services

Obicetrapib: A selective CETP inhibitor in clinical trials
Research and development of therapies for metabolic diseases
Focus on enhancing therapeutic options for patients

Growth Outlook

Strong pipeline with potential for significant market impact
Clinical trials showing promising results for obicetrapib
Increasing demand for effective metabolic disease treatments

Financial Highlights

Recent quarterly revenue of $3.04 million, reflecting ongoing development
Cash and short-term investments totaling $636.1 million as of March 2026
Operating expenses of $60.96 million, indicating investment in R&D

NewAmsterdam Pharma Company N.V. is positioned in the biotechnology sector, with a focus on addressing unmet medical needs in metabolic diseases. The company's innovative approach and strong financial backing provide a solid foundation for future growth. With a robust pipeline and promising clinical data, NewAmsterdam Pharma is well-placed to capitalize on the increasing demand for effective treatments in this area.

AI Generated • Jul 20, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Naarden, NH 1411 DC, NL

NAMSW Financials

Key Financial Metrics (TTM)

Gross Margin

97.52%

Operating Margin

-953.59%

Net Income Margin

-942.76%

Return on Equity

-29.80%

Return on Capital

-33.01%

Return on Assets

-29.04%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

Avg. Volume

761.581

Financials (TTM)

Gross Profit

$22.01M

Operating Income

-$215.18M

EBITDA

-$212.50M

Operating Cash Flow

-$141.92M

Capital Expenditure

-$268.00K

Free Cash Flow

-$142.19M

Cash & ST Invst.

$636.11M

Total Debt

$23.00K

NewAmsterdam Pharma Performance Analysis

NewAmsterdam Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	542.9%
Q3	2025-09-30	-98.2%
Q4	2025-12-31	-90.8%
Q1	2026-03-31	9400.0%

NewAmsterdam Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	55.9%
Q3	2025-09-30	-306.7%
Q4	2025-12-31	-6.6%
Q1	2026-03-31	38.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$3.04M

+2.1%

Gross Profit

$2.54M

-14.7%

Gross Margin

83.55%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

100

N/A

Net Income

-$48.44M

-22.6%

EBITDA

-$48.38M

-22.6%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$636.11M

-21.3%

Total Debt

$23.00K

-94.1%

Accounts Receivable

$8.22M

+409.7%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$23.00K

-90.9%

Return on Assets

-29.04%

N/A

Return on Invested Capital

-32.35%

N/A

Free Cash Flow

-$30.64M

+16.0%

Operating Cash Flow

-$30.60M

+16.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SRRKScholar Rock Holding Corporation

SRRKScholar Rock Holding Corporation$48.93+2.64%

VCYTVeracyte, Inc.

VCYTVeracyte, Inc.$55.61-1.77%

IDYAIDEAYA Biosciences, Inc.

IDYAIDEAYA Biosciences, Inc.$36.77+3.87%

KNSAKiniksa Pharmaceuticals International, plc

KNSAKiniksa Pharmaceuticals International, plc$63.54+1.11%

ZLABZai Lab Limited

ZLABZai Lab Limited$18.64-3.02%

FOLDAmicus Therapeutics, Inc.

FOLDAmicus Therapeutics, Inc.$14.49+0.00%

TARSTarsus Pharmaceuticals, Inc.

TARSTarsus Pharmaceuticals, Inc.$60.12+2.49%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.25+0.10%

NOKNokia

NOKNokia$9.28+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.95+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.24-0.02%

TAT&T

TAT&T$24.42+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.40-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.88+0.03%

Questions About NAMSW

What is the current price of NewAmsterdam Pharma?

NewAmsterdam Pharma is trading at $19.40 per share.

What is the 52-week range for NewAmsterdam Pharma?

Over the past 52 weeks, NewAmsterdam Pharma has traded between $10.23 and $30.45.

How much debt does NewAmsterdam Pharma have?

NewAmsterdam Pharma total debt is unavailable.

How much cash does NewAmsterdam Pharma have on hand?

NewAmsterdam Pharma does not have cash on hand data available.

What is NewAmsterdam Pharma’s dividend yield?

NewAmsterdam Pharma does not currently have a dividend yield.

NewAmsterdam Pharma(NASDAQ) NAMSW

NewAmsterdam Pharma Financials at a Glance

NAMSW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About NewAmsterdam Pharma

NAMSW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

NewAmsterdam Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NAMSW

What is the current price of NewAmsterdam Pharma?

What is the 52-week range for NewAmsterdam Pharma?

How much debt does NewAmsterdam Pharma have?

How much cash does NewAmsterdam Pharma have on hand?

What is NewAmsterdam Pharma’s dividend yield?

Premium Investing Services